Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA?? (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)

GlobeNewswire June 26, 2019

Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference

GlobeNewswire May 31, 2019

Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA(TM) Injection in Hemodialysis Patients with Pruritus

GlobeNewswire May 29, 2019

Cannabis Stock Releases Huge News this week-THC Therapeutics, Inc.

Press Releases May 10, 2019

Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

GlobeNewswire May 8, 2019

Cara Therapeutics Reports First Quarter 2019 Financial Results

GlobeNewswire May 7, 2019

Cara Therapeutics to Announce First Quarter 2019 Financial Results on May 7, 2019

GlobeNewswire April 30, 2019

CBD Company to Research Now

Press Releases April 16, 2019

68 Biggest Movers From Yesterday

Benzinga.com  March 14, 2019

48 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  March 13, 2019

40 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  March 13, 2019

The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

Benzinga.com  March 13, 2019

The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Benzinga.com  March 12, 2019

66 Biggest Movers From Friday

Benzinga.com  February 11, 2019

Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ (CR845/ difelikefalin) Injection in Hemodialysis Patients with Pruritus

GlobeNewswire January 7, 2019

66 Biggest Movers From Yesterday

Benzinga.com  January 3, 2019

45 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  January 2, 2019

Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

GlobeNewswire January 2, 2019

Cara Therapeutics to Present at November Investor Conferences

GlobeNewswire November 8, 2018

Cara Therapeutics Reports Third Quarter 2018 Financial Results

GlobeNewswire November 6, 2018